
EU orders 100 million additional doses from Biontech
To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

Novel COVID antibody enters clinical testing
In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

Immunocore bags US$75m in Series C round
The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

EU life science PPPs face less budget in Horizon Europe
The EU’s Public-Private Partnerships (PPPs), which have been under fire by the European Parliament and were renamed into ‘European Partnerships‘, are...

Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

BioPhero A/S raises US$17m in Series A funding
New investor exFMC Ventures, as well as existing investors Syngenta Group Ventures and Novo Holdings also participated in the...